Rigel Pharmaceuticals Inc. (New) (RIGL)

Price$29.86

Value ScoreA

Growth ScoreB

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-46.38%

Price vs S&P 500 (4W)-1.26%

VGM Score65.32

Market Capitalization$564.13M

P/E Ratio (Annual)1.54x

All Metrics

P/CF (Annual)7.46x

Book Value / Share (Quarterly)$21.64

P/TBV (Annual)2.12x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)34.78%

Cash Flow / Share (Quarterly)$4.29

Price vs S&P 500 (YTD)-39.75%

Gross Margin (TTM)93.39%

Net Profit Margin (TTM)121.51%

EPS (TTM)$18.43

10-Day Avg Trading Volume0.35M

EPS Excl Extra (TTM)$18.43

Revenue Growth (5Y)22.06%

EPS (Annual)$19.48

ROI (Annual)82.71%

Gross Margin (Annual)93.33%

Net Profit Margin (5Y Avg)10.45%

Cash / Share (Quarterly)$7.94

P/E Basic Excl Extra (TTM)1.55x

Revenue Growth QoQ (YoY)10.28%

P/E Normalized (Annual)1.54x

ROA (Last FY)71.46%

Revenue Growth TTM (YoY)47.61%

EBITD / Share (TTM)$6.55

ROE (5Y Avg)70.99%

Operating Margin (TTM)41.56%

Cash Flow / Share (Annual)$4.13

P/B Ratio1.41x

P/B Ratio (Quarterly)1.25x

Net Income / Employee (Annual)$2,133,900

EV / Revenue (TTM)1.95x

Net Interest Coverage (TTM)34.48x

ROA (TTM)99.28%

EPS Growth QoQ (YoY)-30.22%

EV / EBITDA (TTM)4.63x

EPS Incl Extra (Annual)$19.48

Current Ratio (Annual)2.42x

Quick Ratio (Quarterly)2.20x

3-Month Avg Trading Volume0.37M

52-Week Price Return56.12%

EV / Free Cash Flow (Annual)7.73x

P/E Incl Extra (TTM)1.55x

Revenue / Employee (TTM)$1,742,800

Tangible BV / Share (Quarterly)$20.33

P/S Ratio (Annual)1.92x

Asset Turnover (Annual)0.57x

52-Week High$52.24

Operating Margin (5Y Avg)-3.21%

EPS Excl Extra (Annual)$19.48

CapEx CAGR (5Y)-22.97%

26-Week Price Return-30.45%

Quick Ratio (Annual)2.08x

13-Week Price Return-14.62%

Total Debt / Equity (Annual)0.13x

Current Ratio (Quarterly)2.62x

Enterprise Value$584.57M

Revenue / Share Growth (5Y)89.25%

Asset Turnover (TTM)0.82x

Book Value / Share Growth (5Y)100.65%

Revenue / Employee (Annual)$1,710,900

Inventory Turnover (Annual)2.24x

Pretax Margin (Annual)41.40%

Cash / Share (Annual)$8.46

3-Month Return Std Dev56.16%

Gross Margin (5Y Avg)94.95%

Net Income / Employee (TTM)$2,117,600

EBITDA Interim CAGR (5Y)-22.31%

ROE (Last FY)93.75%

Net Interest Coverage (Annual)47.82x

EPS Basic Excl Extra (Annual)$19.48

P/FCF (TTM)7.12x

Receivables Turnover (TTM)6.55x

EV / Free Cash Flow (TTM)7.37x

Total Debt / Equity (Quarterly)0.11x

EPS Incl Extra (TTM)$18.43

Receivables Turnover (Annual)6.30x

ROI (TTM)120.65%

P/S Ratio (TTM)1.88x

Pretax Margin (5Y Avg)-6.04%

Revenue / Share (Annual)$15.62

Tangible BV / Share (Annual)$20.03

Forward P/E8.62x

Price vs S&P 500 (52W)27.91%

P/E Ratio (TTM)1.55x

EPS Growth TTM (YoY)788.81%

Year-to-Date Return-28.81%

5-Day Price Return5.10%

EPS Normalized (Annual)$19.48

ROA (5Y Avg)1.28%

Net Profit Margin (Annual)124.72%

Month-to-Date Return5.50%

Cash Flow / Share (TTM)$-0.14

EBITD / Share (Annual)$6.79

Operating Margin (Annual)42.63%

LT Debt / Equity (Annual)0.06x

P/CF (TTM)7.12x

ROI (5Y Avg)-17.10%

P/E Excl Extra (TTM)1.55x

LT Debt / Equity (Quarterly)0.04x

EPS Basic Excl Extra (TTM)$18.43

P/TBV (Quarterly)1.33x

P/B Ratio (Annual)1.99x

Inventory Turnover (TTM)2.43x

Pretax Margin (TTM)40.69%

Book Value / Share (Annual)$21.38

Price vs S&P 500 (13W)-24.36%

Beta1.20x

P/FCF (Annual)7.46x

Revenue / Share (TTM)$15.23

ROE (TTM)147.03%

52-Week Low$18.14

vGradeA

gGradeB

mGradeC

vgmGradeB

Show chart for

Earnings Surprise History

Q1 260.44est. 0.70

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.00

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
RIGLRigel Pharmaceuticals Inc. (New)	A	B	C	$29.86
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Rigel Pharmaceuticals develops small-molecule therapeutics for autoimmune, cancer, and viral diseases. The company markets TAVALISSE, an oral SYK inhibitor, and generates revenue through a partnership with AstraZeneca for an oral rheumatoid arthritis candidate, earning royalties and milestone payments. Its pipeline includes additional candidates targeting SYK and JAK pathways.